Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2002

View Archived Issues

A possible role for the Rho kinase-mediated signaling pathway in asthma

R-115777 radiosensitizes previously radioresistant human glioma cells

Successful treatment of severe alcoholic hepatitis with urinastarine

Modafinil improves symptoms in children with spastic cerebral palsy

Y-931 is less sensitive to oxidative phenomena than other antipsychotics

ZYC-101a shows potential in the treatment of anal dysplasia

KF-26777 may be useful in the treatment of brain ischemia

Sanofi-Synthelabo describes new agent for the treatment of AD

Diovan receives approval as heart failure therapy in U.S.

Abbott describes novel alphavbeta3 receptor modulators with potential in cardiovascular disorders

New antiprotozoal compounds prepared and tested by Akzo Nobel researchers

Selective thrombin inhibitors identified by LEK and University of Ljubljana researchers

Rambaxy identifies novel antifungal compounds

Phase III study of Antisoma's pemtumomab expected to be completed in 2004

Schering AG in-licenses further rights to fasudil

Vernalis to report findings from frovatriptan menstrual migraine trial next month

Aventis seeking U.S. marketing approval for Ketek

Potassium channel openers for use in bladder overactivity presented by Abbott at ACS

Early clinical data discussed for the adenosine A1 antagonist BG-9928

Discovery of novel PPARalpha agonists and selection of a clinical candidate

Discovery and synthesis of the clinical candidate CP-608039 reported at ACS

Millennium reports SAR studies on melanocortin MC-4 antagonists